cytochrome P450 family 7 subfamily A member 1Genealiases: CP7A · CYP7 · CYPVII
Q-omics provides the consensus-scored CYP7A1 profile across patient tissues and cancer cell-line models. CYP7A1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CYP7A1 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, CYP7A1 RNA expression shows 15,560 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, LUAD, and UVM as cancer lineages where CYP7A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP7A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP7A1 survival associations across molecular data types. CYP7A1 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP7A1 RNA expression–survival associations across cancer types. High CYP7A1 expression shows favorable associations in MESO, ESCA, ACC, LIHC, BRCA and CESC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for CYP7A1 RNA expression.
This table summarizes CYP7A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CYP7A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP7A1 shows lower tumor expression in LUAD, THCA, KICH, BLCA, BRCA and LUSC. The LUAD box plot shows higher CYP7A1 RNA expression in normal versus tumor tissue (log2 FC = −0.165, t-test p < 0.001).
This table shows molecular features associated with CYP7A1 in patient tissues and cancer cell lines. In patient samples, CYP7A1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP7A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
